MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

Kemas kini terakhir: 6 hari lalu, 11:18AM

89.26

0.03 (0.03%)

  • 1H 0.03%
  • 5H -3.30%
  • 1B -5.04%
  • 6B -17.80%
  • Tahun Ke Tarikh -9.99%
  • 1T -29.47%
  • 5T 16.48%
Penutupan Terdahulu 89.23
Buka 89.25
Jumlah Dagangan 3,938,439
Purata Dagangan (3B) 16,066,484
Modal Pasaran 225,474,347,008
Harga / Pendapatan (P/E TTM) 13.24
Harga / Pendapatan (P/E Ke hadapan) 9.73
Harga / Jualan (P/S) 3.47
Harga / Buku (P/B) 4.78
Julat 52 Minggu
81.04 (-9%) — 134.63 (50%)
Tarikh Pendapatan 24 Apr 2025
Hasil Dividen (DY TTM) 3.50%
Margin Keuntungan 26.67%
Margin Operasi (TTM) 34.19%
EPS Cair (TTM) 6.74
Pertumbuhan Hasil Suku Tahunan (YOY) 6.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -33.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 82.53%
Nisbah Semasa (MRQ) 1.37
Aliran Tunai Operasi (OCF TTM) 21.47 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 17.83 B
Pulangan Atas Aset (ROA TTM) 13.90%
Pulangan Atas Ekuiti (ROE TTM) 40.79%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok Merck & Company, Inc. Menurun Menurun

AISkor Stockmoo

1.4
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga 3.5
Purata Bergerak Teknikal 3.5
Osilator Teknikal -2.5
Purata 1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
MRK 225 B 3.50% 13.24 4.78
NVS 222 B 3.54% 19.18 4.89
LLY 663 B 0.73% 62.88 52.04
NVO 295 B 2.40% 20.46 16.26
JNJ 369 B 3.24% 26.47 5.39
ABBV 367 B 3.03% 87.24 109.22

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Core
% Dimiliki oleh Orang Dalam 0.07%
% Dimiliki oleh Institusi 80.43%
148.25148.25132.50132.50116.75116.75101.00101.0085.2585.25Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
81.04 (-9%) — 134.63 (50%)
Julat Harga Sasaran
96.00 (7%) — 120.00 (34%)
Tinggi 120.00 (UBS, 34.44%) Beli
Median 112.00 (25.48%)
Rendah 96.00 (BMO Capital, 7.55%) Pegang
Purata 110.89 (24.23%)
Jumlah 5 Beli, 4 Pegang
Harga Purata @ Panggilan 92.04
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Deutsche Bank 18 Feb 2025 105.00 (17.63%) Pegang 83.29
Guggenheim 12 Feb 2025 115.00 (28.84%) Beli 85.67
B of A Securities 05 Feb 2025 112.00 (25.48%) Beli 89.67
BMO Capital 05 Feb 2025 96.00 (7.55%) Pegang 89.67
Citigroup 05 Feb 2025 115.00 (28.84%) Beli 89.67
28 Jan 2025 125.00 (40.04%) Beli 97.45
Morgan Stanley 05 Feb 2025 106.00 (18.75%) Pegang 89.67
21 Jan 2025 113.00 (26.60%) Pegang 96.24
Leerink Partners 13 Jan 2025 119.00 (33.32%) Beli 100.98
Truist Securities 08 Jan 2025 110.00 (23.24%) Pegang 99.85
UBS 08 Jan 2025 120.00 (34.44%) Beli 99.85
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
01 Apr 2025 Pengumuman Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
31 Mar 2025 Pengumuman WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
27 Mar 2025 Pengumuman Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
26 Mar 2025 Pengumuman European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
25 Mar 2025 Pengumuman Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
19 Mar 2025 Pengumuman Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
12 Mar 2025 Pengumuman Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
11 Mar 2025 Pengumuman Merck Unveils New Facility to Increase Vaccine Production Capacity
25 Feb 2025 Pengumuman FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
24 Feb 2025 Pengumuman Merck to Participate in the TD Cowen 45th Annual Health Care Conference
18 Feb 2025 Pengumuman WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
13 Feb 2025 CNBC U.S. investors, Big Pharma race to find new medicines in China
10 Feb 2025 CNBC Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
06 Feb 2025 Pengumuman Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
04 Feb 2025 CNBC Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
04 Feb 2025 Pengumuman Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
04 Feb 2025 Pengumuman Merck Canada urges Canadians to take action for their lung health with new “Listen Close” campaign
31 Jan 2025 Pengumuman Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
30 Jan 2025 Pengumuman Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
28 Jan 2025 Pengumuman Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
27 Jan 2025 Pengumuman FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
27 Jan 2025 CNBC Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
24 Jan 2025 Pengumuman Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
16 Jan 2025 Pengumuman Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
08 Jan 2025 Pengumuman Merck’s GARDASIL® Receives Expanded Approval for Males in China
06 Jan 2025 Pengumuman Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Papar semua
Hasil Dividen (DY TTM) 3.50%
Purata Hasil Dividen 5T 2.96%
Nisbah Pembayaran 46.29%
Jangkaan Pembayaran Dividen Seterusnya Jul 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
17 Mar 2025 28 Jan 2025 07 Apr 2025 0.81 Tunai
16 Dec 2024 19 Nov 2024 08 Jan 2025 0.81 Tunai
16 Sep 2024 23 Jul 2024 07 Oct 2024 0.77 Tunai
17 Jun 2024 28 May 2024 08 Jul 2024 0.77 Tunai
14 Mar 2024 23 Jan 2024 05 Apr 2024 0.77 Tunai
14 Dec 2023 28 Nov 2023 08 Jan 2024 0.77 Tunai
14 Sep 2023 25 Jul 2023 06 Oct 2023 0.73 Tunai
14 Jun 2023 23 May 2023 10 Jul 2023 0.73 Tunai
14 Mar 2023 24 Jan 2023 10 Apr 2023 0.73 Tunai
14 Dec 2022 29 Nov 2022 09 Jan 2023 0.73 Tunai
14 Sep 2022 26 Jul 2022 07 Oct 2022 0.69 Tunai
14 Jun 2022 24 May 2022 08 Jul 2022 0.69 Tunai
14 Mar 2022 25 Jan 2022 07 Apr 2022 0.69 Tunai
14 Dec 2021 30 Nov 2021 07 Jan 2022 0.69 Tunai
14 Sep 2021 27 Jul 2021 07 Oct 2021 0.65 Tunai
14 Jun 2021 25 May 2021 07 Jul 2021 0.65 Tunai
12 Mar 2021 26 Jan 2021 07 Apr 2021 0.65 Tunai
14 Dec 2020 17 Nov 2020 08 Jan 2021 0.65 Tunai
14 Sep 2020 28 Jul 2020 07 Oct 2020 0.61 Tunai
12 Jun 2020 26 May 2020 07 Jul 2020 0.61 Tunai
13 Mar 2020 28 Jan 2020 07 Apr 2020 0.61 Tunai
13 Dec 2019 20 Nov 2019 08 Jan 2020 0.61 Tunai
13 Sep 2019 24 Jul 2019 07 Oct 2019 0.55 Tunai
14 Jun 2019 29 May 2019 08 Jul 2019 0.55 Tunai
14 Mar 2019 30 Jan 2019 05 Apr 2019 0.55 Tunai
14 Dec 2018 26 Oct 2018 08 Jan 2019 0.55 Tunai
14 Sep 2018 25 Jul 2018 05 Oct 2018 0.48 Tunai
14 Jun 2018 23 May 2018 09 Jul 2018 0.48 Tunai
14 Mar 2018 24 Jan 2018 06 Apr 2018 0.48 Tunai
14 Dec 2017 29 Nov 2017 08 Jan 2018 0.48 Tunai
14 Sep 2017 26 Jul 2017 06 Oct 2017 0.47 Tunai
13 Jun 2017 24 May 2017 10 Jul 2017 0.47 Tunai
13 Mar 2017 28 Feb 2017 07 Apr 2017 0.47 Tunai
13 Dec 2016 22 Nov 2016 09 Jan 2017 0.47 Tunai
13 Sep 2016 26 Jul 2016 07 Oct 2016 0.46 Tunai
13 Jun 2016 25 May 2016 08 Jul 2016 0.46 Tunai
11 Mar 2016 24 Feb 2016 07 Apr 2016 0.46 Tunai
11 Dec 2015 24 Nov 2015 08 Jan 2016 0.46 Tunai
11 Sep 2015 22 Jul 2015 07 Oct 2015 0.45 Tunai
11 Jun 2015 26 May 2015 08 Jul 2015 0.45 Tunai
12 Mar 2015 24 Feb 2015 08 Apr 2015 0.45 Tunai
11 Dec 2014 25 Nov 2014 08 Jan 2015 0.45 Tunai
11 Sep 2014 23 Jul 2014 07 Oct 2014 0.44 Tunai
12 Jun 2014 27 May 2014 08 Jul 2014 0.44 Tunai
13 Mar 2014 25 Feb 2014 07 Apr 2014 0.44 Tunai
12 Dec 2013 26 Nov 2013 08 Jan 2014 0.44 Tunai
12 Sep 2013 23 Jul 2013 07 Oct 2013 0.43 Tunai
13 Jun 2013 28 May 2013 08 Jul 2013 0.43 Tunai
13 Mar 2013 26 Feb 2013 05 Apr 2013 0.43 Tunai
13 Dec 2012 27 Nov 2012 08 Jan 2013 0.43 Tunai
13 Sep 2012 24 Jul 2012 05 Oct 2012 0.42 Tunai
13 Jun 2012 22 May 2012 09 Jul 2012 0.42 Tunai
13 Mar 2012 28 Feb 2012 06 Apr 2012 0.42 Tunai
13 Dec 2011 10 Nov 2011 09 Jan 2012 0.42 Tunai
13 Sep 2011 26 Jul 2011 07 Oct 2011 0.38 Tunai
13 Jun 2011 24 May 2011 08 Jul 2011 0.38 Tunai
11 Mar 2011 22 Feb 2011 07 Apr 2011 0.38 Tunai
13 Dec 2010 23 Nov 2010 07 Jan 2011 0.38 Tunai
13 Sep 2010 27 Jul 2010 07 Oct 2010 0.38 Tunai
11 Jun 2010 26 May 2010 08 Jul 2010 0.38 Tunai
11 Mar 2010 23 Feb 2010 07 Apr 2010 0.38 Tunai
11 Dec 2009 24 Nov 2009 08 Jan 2010 0.38 Tunai
02 Sep 2009 28 Jul 2009 01 Oct 2009 0.38 Tunai
04 Jun 2009 27 May 2009 01 Jul 2009 0.38 Tunai
04 Mar 2009 24 Feb 2009 01 Apr 2009 0.38 Tunai
03 Dec 2008 25 Nov 2008 02 Jan 2009 0.38 Tunai
03 Sep 2008 22 Jul 2008 01 Oct 2008 0.38 Tunai
04 Jun 2008 27 May 2008 01 Jul 2008 0.38 Tunai
05 Mar 2008 26 Feb 2008 01 Apr 2008 0.38 Tunai
05 Dec 2007 27 Nov 2007 02 Jan 2008 0.38 Tunai
05 Sep 2007 24 Jul 2007 01 Oct 2007 0.38 Tunai
06 Jun 2007 22 May 2007 02 Jul 2007 0.38 Tunai
07 Mar 2007 27 Feb 2007 02 Apr 2007 0.38 Tunai
06 Dec 2006 28 Nov 2006 02 Jan 2007 0.38 Tunai
30 Aug 2006 25 Jul 2006 02 Oct 2006 0.38 Tunai
31 May 2006 23 May 2006 03 Jul 2006 0.38 Tunai
31 Aug 2005 26 Jul 2005 03 Oct 2005 0.38 Tunai
01 Jun 2005 24 May 2005 01 Jul 2005 0.38 Tunai
02 Mar 2005 22 Feb 2005 01 Apr 2005 0.38 Tunai
01 Dec 2004 23 Nov 2004 03 Jan 2005 0.38 Tunai
01 Sep 2004 27 Jul 2004 01 Oct 2004 0.38 Tunai
02 Jun 2004 25 May 2004 01 Jul 2004 0.37 Tunai
03 Mar 2004 24 Feb 2004 01 Apr 2004 0.37 Tunai
03 Dec 2003 25 Nov 2003 02 Jan 2004 0.37 Tunai
03 Sep 2003 22 Jul 2003 01 Oct 2003 0.37 Tunai
04 Jun 2003 27 May 2003 01 Jul 2003 0.36 Tunai
05 Mar 2003 25 Feb 2003 01 Apr 2003 0.36 Tunai
04 Dec 2002 26 Nov 2002 02 Jan 2003 0.36 Tunai
04 Sep 2002 23 Jul 2002 01 Oct 2002 0.36 Tunai
05 Jun 2002 28 May 2002 01 Jul 2002 0.35 Tunai
06 Mar 2002 26 Feb 2002 01 Apr 2002 0.35 Tunai
05 Dec 2001 27 Nov 2001 02 Jan 2002 0.35 Tunai
30 Aug 2001 24 Jul 2001 01 Oct 2001 0.35 Tunai
31 May 2001 22 May 2001 02 Jul 2001 0.34 Tunai
07 Mar 2001 27 Feb 2001 02 Apr 2001 0.34 Tunai
06 Dec 2000 28 Nov 2000 02 Jan 2001 0.34 Tunai
30 Aug 2000 25 Jul 2000 02 Oct 2000 0.34 Tunai
31 May 2000 22 May 2000 03 Jul 2000 0.29 Tunai
01 Mar 2000 22 Feb 2000 03 Apr 2000 0.29 Tunai
01 Dec 1999 23 Nov 1999 03 Jan 2000 0.29 Tunai
01 Sep 1999 27 Jul 1999 01 Oct 1999 0.29 Tunai
02 Jun 1999 25 May 1999 01 Jul 1999 0.27 Tunai
03 Mar 1999 23 Feb 1999 01 Apr 1999 0.27 Tunai
02 Dec 1998 24 Nov 1998 04 Jan 1999 0.54 Tunai
02 Sep 1998 28 Jul 1998 01 Oct 1998 0.54 Tunai
03 Jun 1998 26 May 1998 01 Jul 1998 0.45 Tunai
04 Mar 1998 24 Feb 1998 01 Apr 1998 0.45 Tunai
03 Dec 1997 25 Nov 1997 02 Jan 1998 0.45 Tunai
03 Sep 1997 22 Jul 1997 01 Oct 1997 0.45 Tunai
05 Jun 1997 28 May 1997 01 Jul 1997 0.42 Tunai
05 Mar 1997 25 Feb 1997 01 Apr 1997 0.42 Tunai
05 Dec 1996 26 Nov 1996 02 Jan 1997 0.4 Tunai
04 Sep 1996 23 Jul 1996 01 Oct 1996 0.4 Tunai
06 Jun 1996 29 May 1996 01 Jul 1996 0.34 Tunai
06 Mar 1996 27 Feb 1996 01 Apr 1996 0.34 Tunai
06 Dec 1995 28 Nov 1995 02 Jan 1996 0.34 Tunai
05 Sep 1995 25 Jul 1995 02 Oct 1995 0.34 Tunai
02 Jun 1995 23 May 1995 03 Jul 1995 0.3 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.62 2 1.82
2024 3.08 4 3.10
2023 2.92 4 2.68
2022 2.76 4 2.49
2021 2.60 4 3.39
2020 2.44 4 3.13
2019 2.20 4 2.54
2018 1.92 4 2.63
2017 1.88 4 3.50
2016 1.84 4 3.28
2015 1.80 4 3.57
2014 1.76 4 3.25
2013 1.72 4 3.60
2012 1.68 4 4.30
2011 1.52 4 4.23
2010 1.52 4 4.42
2009 1.52 4 4.36
2008 1.52 4 5.24
2007 1.52 4 2.74
2006 0.760 2 1.83
2005 1.52 4 5.01
2004 1.49 4 4.86
2003 1.45 4 3.29
2002 1.41 4 2.61
2001 1.37 4 2.44
2000 1.21 4 1.35
1999 1.37 4 2.14
1998 1.89 4 2.69
1997 1.69 4 3.34
1996 1.42 4 3.74
1995 0.640 2 2.04
Papar semua
95.9795.9792.7492.7489.5089.5086.2786.2783.0483.04Mar 20Mar 20Mar 21Mar 21Mar 24Mar 24Mar 25Mar 25Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
1.0001.0000.5000.5000.0000.000-0.500-0.500-1.000-1.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda